AbbVie struck a voluntary agreement with the U.S. administration committing up to $100 billion in U.S. research, development and manufacturing investment over the next decade in exchange for policy concessions, including tariff exemptions and support for expanded direct‑to‑patient sales through the TrumpRx program. The company said the pact will expand access programs for listed medicines such as HUMIRA and SYNTHROID. AbbVie framed the pact as addressing affordability and domestic manufacturing while preserving commercial incentives for innovation. The administration touted the agreement as aligned with its drug‑pricing objectives. Details of the deal’s financial mechanics and any regulatory tradeoffs remain confidential, and implementation will require operational changes and continued government collaboration. Industry groups, investors and payers will parse the deal for implications on U.S. drug pricing dynamics, future voluntary manufacturer agreements, and potential precedent for other large biopharma firms negotiating conditional policy relief for expanded domestic investment.